← Back to Clinical Trials
Recruiting NCT06823453

NCT06823453 Reducing Overdose and Substance Use-related Stigma by Training Non-substance-using Friends and Family Members of People Who Use Opioids to Be Harm Reduction Champions

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06823453
Status Recruiting
Phase
Sponsor University of Illinois at Chicago
Condition Opioid Overdose Prevention
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2025-10-28
Primary Completion 2028-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Peer Harm Reduction Support Champion Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2025-10-28 with a primary completion date of 2028-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Fatal opioid overdoses are more frequent among populations with low access to harm reduction (HR) services and with high substance use-related stigma (which is a major barrier to accessing HR services). One such population is older adults who use drugs (PWUD) on the West side of Chicago. Over 34% of Chicago's opioid-related EMS responses in 2023 were located in communities on the West side, but older adults in these communities access HR services at low rates, likely due to stigma and other barriers. To help address these barriers and increase HR service access among this population, the proposed clinical trial will evaluate a novel intervention that will recruit non-substance-using friends and family members of people who use opioids and live on the West side of Chicago, educate them on HR tools and services, and train them to become peer HR support champions. They will be asked to recruit one friend or family member who uses opioids to the study, who will also be provided with an educational training on overdose risk reduction and available HR tools and services. The intervention will then facilitate a counselor-led initial conversation between peer HR support champions and their friend or family member who uses opioids to help establish HR support, and provide all participants with naloxone and fentanyl test strip kits. This intervention will not only provide another mechanism through which PWUD can access HR tools and services, thereby reducing logistical barriers, but should also reduce stigma and increase social support by facilitating and normalizing open conversations about HR between PWUD and their non-PWUD HR support champions. Participants of a previous focus group conducted by the Investigators among West side PWUD thought this intervention would be helpful, said they would be willing to participate in it, and said they knew someone who could participate as their non-PWUD peer HR support champion. To facilitate recruitment of older adults, the Investigative Team will work with local faith-based and service organizations and educate them about the importance of HR. The intervention's efficacy will be evaluated for a) increasing uptake/use of HR services, b) decreasing overdose frequency, and c) decreasing stigma and other barriers to accessing HR services, both i) by examining change over time among intervention participants, and ii) by using propensity-score matching methods to compare outcomes between intervention participants and a comparison group of PWUD who have recently accessed HR services from one of the study's community partners (Community Outreach Intervention Projects or West Side Heroin and Opioid Task Force).

Eligibility Criteria

Eligibility Criteria for Non-PWUD (i.e., people who do not use drugs) Peer Intervention Participants, to Be Trained as Harm Reduction Support Champions. 1) Non-PWUD peers recruited directly to the study (i.e., not by a PWUD peer partner) will be eligible to participate in the intervention arm of the study if they live in Chicago, know someone at least 18 years of age who lives on the West side of Chicago who currently uses opioids (to the best of their knowledge), state that they are interested in learning how to offer social support and practical support to that person, report that they have not used "hard" drugs (drugs other than alcohol or marijuana) recreationally in the last year, are at least 18 years of age, and state that they and the person they want to support are able to be interviewed in English and/or Spanish. 2) Non-PWUD peers recruited to the intervention arm of the study by a study participant they know who uses drugs will be eligible to participate in the intervention if they live in Chicago, report that they have not used "hard" drugs (drugs other than alcohol or marijuana) recreationally in the last year, state that they are willing to learn how to support their peer who uses drugs, are at least 18 years old, and are able to be interviewed in English and/or Spanish. Eligibility Criteria for PWUD Intervention Participants (i.e., intervention participants who use drugs). 1) People who use drugs (PWUD) recruited directly to the intervention arm of the study (i.e., not by a non-PWUD peer partner) by West Side Heroin and Opioid Task Force or snowball sampling will be eligible to participate in the intervention if they live on the West side of Chicago, report that they currently use opioids (i.e., in the last week), know at least one person living in Chicago who has not used opioids in the last year and who they are willing to try to recruit to the study as someone who might be willing to offer them harm reduction support, are at least 18 years old, and are able to be interviewed in English and/or Spanish. 2) PWUD recruited to the intervention arm of the study by their non-PWUD peers who are enrolled in the study will be eligible to participate in the intervention group if they live in Chicago, have a study recruitment coupon from a non-PWUD participant, report that they currently use opioids (i.e., in the last week), state that they are willing to learn how their peer might be able to support them, are at least 18 years of age, and are able to be interviewed in English and/or Spanish. Eligibility Criteria for Non-equivalent Comparison Group Participants. Comparison group participants will be eligible to participate in the comparison arm of the study if they report currently using opioids (i.e., in the last week), have accessed harm reduction services from one of the study's community partners (Community Outreach Intervention Projects; or West Side Heroin and Opioid Task Force) in the last six months, are at least 18 years old, and are able to speak English and/or Spanish. These individuals who are recruited to the comparison group will not be eligible to participate in the intervention unless they are given a recruitment coupon by a non-PWUD peer.

Contact & Investigator

Central Contact

Leslie D. Williams, Ph.D.

✉ lesliedw@uic.edu

📞 312-996-8820

Principal Investigator

Leslie D. Williams, Ph.D.

PRINCIPAL INVESTIGATOR

University of Illinois at Chicago

Frequently Asked Questions

Who can join the NCT06823453 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Overdose Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06823453 currently recruiting?

Yes, NCT06823453 is actively recruiting participants. Contact the research team at lesliedw@uic.edu for enrollment information.

Where is the NCT06823453 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT06823453 clinical trial?

NCT06823453 is sponsored by University of Illinois at Chicago. The principal investigator is Leslie D. Williams, Ph.D. at University of Illinois at Chicago. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology